Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations
Rekha Pal(Angiocrine Bioscience (United States)), Katherine L. Pogue–Geile(NSABP Foundation)
Cited by 11